It has been recognized for decades that patients with autoimmune disorders are at risk for thrombotic events. Perhaps the most well known entity is the antiphospholipid antibody syndrome (APS). In this condition, antiphospholipid antibodies (APL) are markers for an increased risk of recurrent thrombosis and/or pregnancy loss. APS is intimately associated with systemic lupus erythematosus (SLE), and can occur as a primary entity or secondary to SLE. Even in the absence of APL, there is an increased risk of thrombosis that is associated with SLE. In addition to these two autoimmune disorders, it is recognized that the presence of other autoimmune diseases, such as inflammatory bowel disease, rheumatoid arthritis, or Behçet’s disease can increase the risk for thrombotic disease. Finally, while not typically thought of as an autoimmune disease, heparin induced thrombocytopenia (HIT) produces limb- and life-threatening thromboses primarily through an immune mediated component.
Must be logged in to view full article. Log inNot a member? Register for a free NATF membership now.
